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Dear Editor,
We  read  with  great  interest  the  article,  “efficacy  of 
hepatitis B vaccine in those who lost hepatitis B surface 
antigen during follow-up” by Taheri et al. published in 
Hepatitis Monthly (1). In this article, the authors assessed 
the efficacy of HBV vaccine in those who lost their HBsAg 
without seroconverssion to anti-HBs antibody with no 
detectable anti-HBs antibody and HBV DNA in their sera. 
They reported that nearly 24% of chronic HBsAg-positive 
subjects who lost their HBsAg responded to HBV vaccine 
and the remaining cases need to be followed for occult 
HBV infection (OBI). By definition, OBI is the presence of 
HBV DNA in the liver tissue in HBsAg-negative individu-
als. In some cases, HBV DNA can be found in serum. OBI 
is mainly related to a strong suppression of viral activity 
in which host immune response and epigenetic factors 
play major role. As a consequence of this viral suppres-
sion, the amount of circulating HBV DNA is very low (usu-
ally < 200 IU/mL) or even undetectable in OBI cases, so 
the diagnosis of this condition requires a very sensitive 
HBV DNA PCR assay with a detection limit of < 10 copies 
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of HBV DNA per reaction (2). OBI status is significantly as-
sociated with presence of anti-HBV antibodies (anti-HBC 
and anti-HBs antibodies) but what must be remembered 
that more than 20% of cases with HBI are negative for all 
serum markers of HBV infection (3). A number of expla-
nations for the persistence of HBV-DNA in HBsAg-nega-
tive samples have been proposed, including integration 
of HBV DNA into host’s chromosomes, mutations in the 
major hydrophilic loop of the S gene, the window period 
following acute HBV infection, underlying HCV co-infec-
tion, immunosuppression, poor ability of laboratory in 
detection of HBsAg and the presence of immune com-
plexes in which HBsAg may be hidden (4).
As we all know, HBV infection is a serious global health 
problem,  with  two  billion  people  infected  worldwide 
and 360 million suffering from chronic HBV infection 
(5). The prevalence of OBI among HBsAg-negative blood 
donors is quite variable depending on the level of HBV 
endemicity  in  the  populations  in  different  regions  of 
the  world.  In  Europe,  OBI  is  detected  in  the  range  of 
1:2000–1:20,000 donations collected (6). Raimondo et al. 
analyzed liver tissue from patients without liver disease 
and showed a prevalence of 17% of OBI in these individu-
als (7). In fact, OBI may be more prevalent than what we 
know today. The importance of OBI is its contribution to 
several  different  clinical  contexts  including  the  trans-
mission  of  HBV  infection,  the  risk  of  reactivation,  the   Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.Hepat Mon. 2011;11(6):475-476
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contribution to liver disease progression and to the de-
velopment of hepatocellular carcinoma (HCC). There is a 
general agreement that HBsAg-negative blood donations 
containing viral DNA have to be considered as infectious 
and may transmit HBV during blood transfusions.
In  routine  practice,  cases  with  positive  anti-HBc  but 
negative HBsAg and anti-HBs are not uncommon, espe-
cially in regions where the prevalence of hepatitis B is 
high. There are several published studies related to hepa-
titis B vaccination in isolated anti-HBc-positive cases. In a 
study from Korea, the first and third vaccinations caused 
successful immunity in 70.6% and 70.6% in isolated anti-
HBc group, and 34.4% and 81.2% in the control group, re-
spectively (8). A recent study from Turkey, showed that 
the response to hepatitis B vaccination in persistent iso-
lated anti-HBc-positive subjects was 50%, 68.7% and 89.6% 
after the first, second and third vaccination, respectively 
(9). HBsAg may be undetectable due to very low levels 
of the antigen or escape mutations. Selection of a sen-
sitive HBsAg assay which can detect S gene mutants is 
very critical to identify the infection. Evaluation of 17 CE-
marked HBsAg assays showed that analytical sensitivities 
of the assays ranged from 0.009 to 0.05 PEI-U/mL for HB-
sAg “ad” standard and 0.012 to 0.11 PEI-U/mL for the “ay” 
standard. In addition, detection of HBsAg mutants was 
problematic with several assays (10). Similarly, detection 
of anti-HBs is also problematic due to differences among 
the commercial assays. Heijting et al. showed that there 
is a vaccine-dependant discrepancy among some com-
mercial anti-HBs assays and that determination of anti-
HBs level depends on the test and the vaccine (11). Testing 
the samples with a different HBsAg and anti-HBs assay 
could give a different result and help to solve the unde-
termined cases reported in the study of Taheri et al. 
The  occurrence  of  anti-HBs  antibody  response  indi-
cates viral clearance although there are rare exceptions. 
It would be wise to vaccinate cases with isolated anti-HBc 
and negative HBV DNA to decide whether the patient has 
OBI or resolved infection since anti-HBs response to HBV 
vaccine in such individuals is generally accepted as the 
proof of resolved infection (12). Taheri et al. preferred to 
test for antibody response after three doses of vaccine as 
this was the schedule for the control group. Even after the 
third dose, nearly 77% of the cases were non-responders 
which raised the question whether these patients have 
OBI. The answer requires either liver biopsy or long-term 
follow-up as mentioned by the authors of the article. An-
other question about this issue is whether the vaccine 
protects against escape mutants. In a recent study 3.7 
million blood donations were tested with nucleic acid 
testing (NAT) and nine HBV DNA-positive but HBsAg- and 
anti-HBc-negative  donations  were  found.  Surprisingly, 
six  of  the  nine  donors  have  been  vaccinated  and  had 
low levels of anti-HBs (3–100 IU/L). When analyzed, HBV 
strains isolated from three of the vaccinated donors were 
essentially wild type whereas quasi-species and escape 
mutations were found in other three donors. It is con-
cluded that low anti-HBs levels induced by vaccination 
protect against hepatitis B disease and chronic infection 
but favor OBI (13). What must be done is to control anti-
HBs titers in vaccinated persons and to remain the titers 
> 100 IU/L. Generation of new hepatitis B vaccines which 
are protective against to escape mutants might be the 
solution. 
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